Urolithin A for muscle and mitochondria: what the trials actually show
See more of CureMed in your Google results.
Urolithin A is a compound your gut bacteria make from foods like pomegranate and walnuts, and it's sold as a mitochondria-supporting supplement (commonly as Mitopure). The best human trial found it genuinely improved muscle strength, but the specific outcome the study was designed to prove — power output — didn't hit statistical significance. A newer trial in athletes found it eased recovery but didn't improve actual performance. It's a real, active area of research, not a settled win.
Urolithin A is a gut-bacteria metabolite of ellagitannins (found in pomegranate, walnuts, and berries) that activates mitophagy — the recycling of damaged mitochondria. Two placebo-controlled human RCTs exist. The larger one, in middle-aged adults, found a real, statistically significant ~12% improvement in muscle strength, plus lower inflammation and mitochondrial-efficiency markers — but missed its own primary endpoint (peak power output). A newer trial in trained distance runners found lower perceived exertion and less exercise-induced muscle damage, but no significant improvement in actual running performance. No trial has measured lifespan or a hard disease outcome.
- Singh et al. 2022 (Cell Rep Med) — middle-aged adults, 4-month RCT: muscle strength improved ~12% (statistically significant), but the trial's stated primary endpoint, peak power output, was not significantly improved.
- The same trial found clinically meaningful gains in aerobic endurance (VO2peak) and the 6-minute walk test, plus lower CRP and plasma acylcarnitines (inflammation and mitochondrial-efficiency markers).
- Whitfield et al. 2025 (Sports Med) — highly trained male distance runners, 4-week RCT: no significant improvement in actual running performance (3000m time trial), but lower perceived exertion and reduced post-exercise muscle-damage markers.
- A 2021 mechanistic review confirms urolithin A has been shown safe up to 2,500mg/day in a clinical trial.
- No trial in any population has measured lifespan, healthspan, or a hard age-related disease outcome.
Graded by CureMed against human clinical evidence, and reviewed by CureMed Labs.
The main human trial: real strength gain, missed primary endpoint
The trial most often cited for urolithin A is a randomized, placebo-controlled study in middle-aged adults, published in Cell Reports Medicine in 2022. Participants took urolithin A at two different doses for four months.
Singh et al. 2022 — what was measured
| Outcome | Result |
|---|---|
| Peak power output (the trial's stated primary endpoint) | Not significantly improved |
| Muscle strength | ~12% improvement — statistically significant |
| Aerobic endurance (VO2peak) and 6-minute walk test | Clinically meaningful improvement |
| Plasma acylcarnitines and C-reactive protein | Significantly lower (higher mitochondrial efficiency, less inflammation) |
| Mitophagy/mitochondrial-metabolism proteins in muscle biopsies | Significant increase |
A newer trial in trained athletes: recovery, not performance
A 2025 trial in Sports Medicine tested urolithin A (1,000mg/day for 4 weeks) in highly trained male distance runners during an altitude training camp — a different, fitter population than the middle-aged trial above.
Whitfield et al. 2025 — what was measured
| Outcome | Result |
|---|---|
| 3000m time-trial running performance | Not significantly improved vs. placebo |
| Rating of perceived exertion after the time trial | Significantly lower with urolithin A |
| Creatine kinase (a muscle-damage marker) | Significantly reduced vs. placebo |
| VO2max | Larger within-group increase than placebo, but the between-group difference wasn't statistically significant |
| Skeletal-muscle mitophagy markers | A medium-sized effect, not statistically significant |
Dose and safety
- A 2021 mechanistic review reports urolithin A has been shown safe at doses up to 2,500mg/day in a clinical trial.
- The two RCTs above used lower doses over 4 weeks to 4 months (1,000mg/day in the athlete trial; two unspecified doses in the middle-aged trial) — neither tested the 2,500mg/day ceiling for efficacy.
- Most commercial products (commonly sold as Mitopure) provide 500mg per serving.
- No trial has run long enough to establish safety data beyond several months of continuous use.
Frequently asked questions
Does urolithin A actually improve muscle strength?
The best RCT found a statistically significant ~12% improvement in muscle strength in middle-aged adults over 4 months. That result is real, but it was a secondary finding — the trial's primary endpoint, peak power output, was not significantly improved. Treat the strength result as promising, not definitive.
Does urolithin A improve athletic performance?
Not demonstrated. A 2025 trial in trained distance runners found no significant improvement in actual running performance (a 3000m time trial), though it did find lower perceived exertion and reduced muscle-damage markers after hard exercise — real recovery benefits, just not a performance gain.
What dose of urolithin A should I take?
The human RCTs used 1,000mg/day (4 weeks, athletes) or two lower unspecified doses (4 months, middle-aged adults). A separate safety review found no issues up to 2,500mg/day, but that higher dose hasn't itself been tested for effectiveness. Most commercial products provide 500mg per serving.
Does urolithin A extend lifespan?
Not tested. No human trial has measured lifespan, healthspan, or a hard age-related disease outcome from urolithin A. The evidence that exists is about muscle strength, exercise recovery, and mitochondrial biomarkers over weeks to months — a plausible mechanism, not a demonstrated longevity effect.
Keep reading
- Creatine and aging: the best-documented compound in longevity
The compound urolithin A is most often compared against — with a much larger and more consistent trial base.
- Taurine and longevity: what the human evidence actually shows
Another compound with a famous headline result and a narrower human evidence base than the marketing suggests.
More in Supplements
- Best sleep aids, ranked by evidence.
Diphenhydramine stops working in about three nights. Melatonin is modest for insomnia, strong for jet lag. Every OTC sleep aid ranked on its human trials.
- The sleep stack on trial: magnesium threonate, theanine and apigenin against placebo
The Huberman-style sleep stack got its first placebo-controlled trial: in 103 healthy adults over two weeks it did no better than placebo on sleep.
- Creatine without exercise: what the new trial actually found
A 2026 trial reported 1.1 kg (2.4 lb) more lean mass on creatine with no exercise. It rests on 13 people per group, and a scan counts water as lean mass.
- The best vitamins for longevity, ranked by human trial evidence
Vitamin D if your level is low, B12 if you are at risk, magnesium for most. Graded only on human randomised trials, including the two that showed harm.
- Which OTC brands pharmacists recommend most — and where the evidence disagrees
Pharmacists name the same OTC brands every year. For immune support and joint health, the trials behind the two biggest sellers do not back how people use them.
- OTC cold and flu remedies, ranked by evidence
The FDA says the decongestant in most cold products does not work. Zinc works only above a dose most lozenges miss. Every OTC cold remedy ranked on its trials.